OR WAIT null SECS
CDMO’s future greater Boston facility to expand cGMP manufacturing capacity, accelerate commercial drug supply
Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has broken ground at its new production site, which is adjacent to its existing site in Milford, MA, in the greater Boston area. The new 22,000 square-foot Rentschler Biopharma Manufacturing Center US (RBMC US) will add manufacturing cleanroom space and house four new 2,000 L single-use bioreactors.
It is anticipated to be completed by late 2023.
In terms of design, the site features upstream ballroom processing intended for production flexibility. The downstream processing suites contain buffer storage and preparation space—the site is also expected to include expanded quality control (QC), development and warehousing capabilities. From a supply chain management and technological standpoint, the facility will be highly automated and leverage industry 4.0 solutions. It will offer digital and analytical services, such as advanced analytics yield optimization, augmented/virtual reality-enabled operations and no-touch batch releases.
“With Rentschler Biopharma’s contribution to the production of mRNA vaccines to beat the Covid-19 virus, we have seen firsthand how important it is to have highly adaptable capacity and to have the experience and expertise needed to produce new therapeutic modalities, fast,” says Dr. Frank Mathias, CEO of Rentschler Biopharma SE. “The US expansion we have kicked off at the groundbreaking is part of our ongoing plan to strategically grow our business as we support our clients in developing and manufacturing even highly complex molecules. We must always be ready to meet the ongoing and ever-changing challenges of reliably bringing new treatments to patients.”